Campath-1H in intestinal and multivisceral transplantation: preliminary data.
Tzakis
A G
AG
Department of Surgery, University of Miami School of Medicine, Miami, FL 33136, USA.
Kato
T
T
Nishida
S
S
Levi
D
D
Madariaga
J
J
De Faria
W
W
Nery
J
J
Neff
G
G
Kirk
A D
AD
Ruiz
P
P
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation*; D007902:Length of Stay; D007958:Leukocyte Count; D016031:Liver Transplantation / Q000276:immunology; D018655:Lymphocyte Count; D010289:Parenteral Nutrition, Total; D011184:Postoperative Period; D012086:Reoperation; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000276:immunology*; D014781:Viscera / Q000637:transplantation*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016559:Tacrolimus